Paul Serhal, Chairman of the Medical Advisory Board at FutureLife, is an accredited consultant in Reproductive Medicine and a Fellow of the Royal College of Obstetricians and Gynaecologists. He held the position of Honorary Senior Lecturer in Obstetrics and Gynaecology at University College Hospital London. With his extensive academic background, Mr. Serhal has published over 100 articles for books and journals, and he is a sought-after speaker at international conferences.

Dr Amy Barrie is Chief Scientific Officer at FutureLife, where she leads scientific strategy and laboratory excellence across the FutureLife clinic network. Amy studied Physiology at the University of Manchester, Prenatal Genetics and Fetal Medicine at UCL and was awarded her PhD in time-lapse incubation and annotation in 2017. Amy is a Fellow of the Royal College of Pathologists and is a registered Higher Specialist Scientist. With 20 years of experience in embryology, 10 years being in IVF laboratory management, Amy is responsible for driving harmonisation of clinical and laboratory practices, ensuring consistent, high-quality outcomes for patients across multiple countries. She plays a central role in shaping FutureLife’s approach to innovation, integrating new technologies such as AI-driven embryo assessment while maintaining rigorous scientific validation and patient-focused care. Amy’s leadership supports FutureLife in continuing to deliver best-in-class reproductive care through collaboration, continuous improvement, and shared expertise. Dr Barrie is actively engaged in international scientific collaboration and professional initiatives within the field of reproductive medicine, where she is Coordinator for the European Society for Embryology and Human Reproduction Embryology Special Interest Group and a member of the Association of Reproductive Clinical Scientists Executive committee.

Prof. Dr. Gürkan Bozdağ is Scientific Director of Bahçeci Fertility and an internationally recognised specialist in reproductive medicine, reproductive endocrinology and IVF. With more than two decades of clinical, academic and research experience, he has led major reproductive medicine centres at Hacettepe and Koç University before joining Bahçeci in 2023. He currently serves as President of the Turkish Society of Reproductive Medicine (TSRM) and has been a member of the Executive Committee (ExCo) of the European Society of Human Reproduction and Embryology (ESHRE) since 2023. He is widely recognized for his research in ovarian reserve, PCOS, endometriosis and advanced IVF treatments, and has contributed extensively to the advancement of evidence-based reproductive medicine and fertility care.

Dr. Àlex García-Faura is Scientific Director at Institut Marquès and Vice-Chair of Research of the FutureLife Medical Advisory Board. With more than 25 years of experience in reproductive medicine, obstetrics & gynaecology, oncology and clinical research, he is internationally recognised for driving scientific innovation and translating research into better patient care. He has authored nearly 50 peer-reviewed publications, delivered more than 100 presentations at international scientific congresses, and actively contributes to leading scientific organisations including ESHRE, SEGO, SEF, GEDO and GEFF. In 2026, he was appointed Board Member (Vocal) of the Executive Board of the Sterility and Infertility Section of the Spanish Society of Gynecology and Obstetrics (SEGO), reflecting his commitment to advancing research, education and clinical excellence in reproductive medicine.

In 2018, Dr. Štěpán Machač, PhD. joined FutureLife as the Chief Medical Officer. Previously, he held significant roles focusing on reproductive medicine. Graduating from Palacký University of Medicine in Olomouc, he also holds a PhD focusing on Inherited Thrombophilia related to severe OHSS. His career started at the Gynaecology and Obstetrics Clinic at Palacký University Olomouc from 1995 to 2003, where he began focusing on infertility treatment. Prior to his role at FutureLife, between 2006 and 2014, Dr. Machač was the lead IVF doctor for international patients at Reprofit International Clinic. Since 2014, he has overseen the IVF Clinic in Olomouc. Additionally, since 2020, Dr. Machač has been the Chairman of Section of Assisted Reproduction at the Czech Medical Society. He is also an author, writing ad co-writing over 30 lectures and 40 professional articles on assisted reproduction, ovarian hyperstimulation syndrome, and gamma donation.

Victor Montalvo is a member of the Medical Advisory Board at FutureLife. He holds a Degree in Genetics from the Autonomous University of Barcelona, achieved a Master's Degree in Reproductive Biology and Assisted Reproductive Technologies with Honors from both the Autonomous University of Barcelona and Instituto Universitario Dexeus, and obtained a second Master's Degree in Biomedical Research from the International University of La Rioja. Since 2018, Victor has played a key role at Institut Marquès, where he currently leads the Embryology Laboratory. His substantial engagement in the scientific community is highlighted by noteworthy publications and a strong presence at both national and international congresses.

Dr. Marjut Otala is Chief Embryologist and Group Laboratory Director at Ovumia and a member of the FutureLife Medical Advisory Board. With more than 20 years of experience in clinical embryology and IVF laboratory management, she leads the development, quality assurance and harmonisation of laboratory practices across the Ovumia network. She holds a PhD in Reproductive Medicine and is an ESHRE Senior Clinical Embryologist. Dr. Otala has served as President of the Nordic Fertility Society and remains actively involved in reproductive medicine research, with recent publications in international peer-reviewed journals. Her expertise spans clinical embryology, fertility preservation, laboratory quality and new technologies, with a strong focus on translating scientific evidence into safe and effective clinical practice and continuous improvement.

Dr. Pavel Otevřel is Medical Director of Reprofit Brno and a specialist in reproductive medicine with extensive experience in assisted reproduction and gynaecological surgery. After graduating from the Faculty of Medicine at Masaryk University, he specialised in gynaecologic oncology before focusing on fertility treatment, with a particular interest in reproductive ageing and optimising IVF outcomes. Dr. Otevřel serves as Scientific Secretary of the Assisted Reproduction Section of the Czech Gynecological and Obstetrical Society and actively contributes to scientific research, professional publications and international conferences, supporting the advancement of evidence-based reproductive medicine.

A Mexican physician based in Madrid, José brings extensive experience in reproductive medicine and a sophisticated international perspective. Having had the opportunity to learn in some of Europe’s most prestigious fertility programs, he has built a robust global network and a reputation for excellence.  Before joining FutureLife, José founded and led his own clinical group as Medical Director for over 5 years. His unique background—a blend of deep clinical heritage rooted in the origins of IVF in Mexico and a pan-European outlook shaped by his Dutch ancestry—allows him to combine clinical credibility with sharp commercial and operational insight.  In partnership with FutureLife’s medical leadership, José focuses on advancing clinical outcomes and ensuring consistently high standards of care across the Group. He plays a central role in fostering collaboration between clinics, championing evidence-led practices, and strengthening a unified medical culture. As a key representative of FutureLife in leading international forums, José helps shape the Group’s clinical direction as it continues its global expansion.

Dorina Codreanu is a member of the Medical Advisory Board at FutureLife. She graduated from the University of Medicine and Pharmacy of Bucharest in 1998 and began her career at Panait Sarbu Hospital. Over more than 10 years there, she gained extensive experience in complex cases of assisted reproduction, high-risk pregnancies, and specialised surgeries. In 2009, she earned her doctorate in assisted reproduction and received a scholarship for further research on improving fertility treatments. With over 20 years in reproductive medicine, Dorina has taught many students, trained specialists, and been part of the examination commissions for granting competence in assisted reproduction.

Mr Ozkan Ozturk is a Consultant in Fertility and Gynaecology at the Centre for Reproductive and Genetic Health (CRGH) with over 25 years of experience in reproductive medicine. Following his medical degree, MD research degree, and specialist and subspecialist training at University College London Hospital, he was appointed Consultant Gynaecologist and Senior Lecturer at University College London Hospitals NHS Foundation Trust. He served as Deputy Medical Director at CRGH (2010–2022) and Medical Director (2023–2025). Mr Ozturk is a Fellow of the Royal College of Obstetricians and Gynaecologists, holds an MBA and the title of Associate Professor in Obstetrics and Gynaecology. His expertise includes recurrent implantation failure, recurrent miscarriage, reduced ovarian reserve, reproductive endocrinology and immunology, male factor infertility, and hysteroscopic surgery. He has published extensively in reproductive medicine and is committed to delivering personalised, evidence-based fertility care.

Dr. Antti Perheentupa is Medical Director at Ovumia and a member of the FutureLife Medical Advisory Board. A specialist in obstetrics and gynaecology, Associate Professor of Reproductive Medicine and an expert in andrology, he has more than 20 years of experience in fertility care, clinical leadership and medical education. Before joining Ovumia, he led the Reproductive Medicine Unit at Turku University Hospital for nearly 15 years and has trained fertility specialists while supervising doctoral research. His clinical and scientific expertise focuses on male infertility, endometriosis and reproductive medicine. Dr. Perheentupa has held several prominent leadership positions within the international fertility community, currently serving as Assistant Treasurer of the International Federation of Fertility Societies (IFFS). He is a former Chair of the Finnish Fertility Society and has also served on the Board of the Nordic Fertility Society. Earlier in his career, he was a Marie Curie Postdoctoral Research Fellow at the MRC Reproductive Biology Unit in Edinburgh, Scotland (1996–1998). Through his clinical, academic and international leadership, he supports the continuous advancement of evidence-based, patient-centred fertility care across the FutureLife network.

Maximiliano Beltramo is IVF Laboratory Manager at ReproMed Galway, Ireland, and a Senior Clinical Embryologist with extensive experience in assisted reproductive technologies and IVF laboratory management. He holds specialist qualifications in clinical embryology, is an ESHRE-certified Clinical Embryologist, and is currently a PhD candidate in Medical Sciences, with a focus on Reproductive Genetics. He was a member of the Executive Committee of the Association of Irish Clinical Embryologists (ICE), serving as Secretary until February 2026. Mr Beltramo has expertise across all aspects of clinical embryology, including embryo culture and assessment, IVF-ICSI, cryopreservation, Preimplantation genetic testing, laboratory quality management, and the implementation of evidence-based innovations to optimise IVF outcomes. His research interests focus on reproductive genetics, reproductive medicine, and clinical embryology, and he has authored and co-authored peer-reviewed scientific publications and book chapters in the field. He regularly presents scientific work at national and international scientific meetings. Passionate about advancing laboratory excellence and patient care, Mr Beltramo is committed to improving clinical outcomes through innovation, quality assurance, and multidisciplinary collaboration in reproductive medicine.